There is not a single pharmaceutical that halts or even slows any neurodegenerative disease. Mounting evidence shows that prions cause many neurodegenerative diseases, and arguably, scrapie and Creutzfeldt-Jakob disease prions represent the best therapeutic targets. We report here that the previously identified 2-aminothiazoles IND24 and IND81 doubled the survival times of scrapie-infected, wild-type mice. However, mice infected with Rocky Mountain Laboratory (RML) prions, a scrapie-derived strain, and treated with IND24 eventually exhibited neurological dysfunction and died. We serially passaged their brain homogenates in mice and cultured cells. We found that the prion strain isolated from IND24-treated mice, designated RML[IND24], emerged during a single passage in treated mice. Although RML prions infect both the N2a and CAD5 cell lines, RML[IND24] prions could only infect CAD5 cells. When passaged in CAD5 cells, the prions remained resistant to high concentrations of IND24. However, one passage of RML [IND24] prions in untreated mice restored susceptibility to IND24 in CAD5 cells. Although IND24 treatment extended the lives of mice propagating different prion strains, including RML, another scrapie-derived prion strain ME7, and chronic wasting disease, it was ineffective in slowing propagation of Creutzfeldt-Jakob disease prions in transgenic mice. Our studies demonstrate that prion strains can acquire resistance upon exposure to IND24 that is lost upon passage in mice in the absence of IND24. These data suggest that monotherapy can select for resistance, thus intermittent therapy with mixtures of antiprion compounds may be required to slow or stop neurodegeneration.
drug discovery | antiprion therapeutics | bioluminescence imaging M ounting evidence argues that many, if not all neurodegenerative illnesses are caused by prions, including such common disorders as Alzheimer's and Parkinson diseases (1, 2) . At present, there is not a single medication that halts or even slows neurodegeneration, which is invariably fatal. Perhaps the most well understood prion diseases are those caused by the aberrantly folded prion protein (PrP) (3, 4) . In humans, PrP prions cause kuru, Creutzfeldt-Jakob disease (CJD), GerstmannSträussler-Scheinker disease and fatal insomnia; in animals, they include scrapie in sheep, bovine spongiform encephalopathy, transmissible mink encephalopathy, and chronic wasting disease (CWD).
Prions are composed of proteins with an alternative conformation that is self-propagating. PrP prions consist of a diseasecausing isoform designated PrP Sc , which is derived from the normal cellular isoform, PrP C . The conversion of PrP C into PrP Sc occurs posttranslationally by a poorly understood process. In fungi, prion formation depends on several different chaperones, but no similar auxiliary proteins have been identified in mammalian prion formation despite evidence for their existence (5) . For many years, the existence of distinct strains of prions was used as an argument against infectious proteins devoid of nucleic acid. Studies of PrP Sc in two transmissible mink encephalopathy strains demonstrated differences in the properties of the protein (6) , while two human mutant PrP Sc prions induced different strains composed of wild-type prions on passage in transgenic (Tg) mice (7) . The number of different PrP Sc conformers that encipher different prion strain-specific properties was initially thought to be relatively few but that view has changed with the recognition that many different strains of synthetic prions can be created de novo and passaged in fungi and mammals (8, 9) . The antimalarial compound quinacrine was found to reduce prion accumulation in cell culture (10, 11) . However, when mice were inoculated with Rocky Mountain Laboratory (RML) prions, a mouse-adapted scrapie strain, and treated with quinacrine, there was no extension in survival and drug-resistant prions emerged (12, 13) . When Weissmann and co-workers added swainsonine (swa) to RML-infected cultured cells, they were able to isolate swa-resistant and swa-dependent RML strains (14) . Because swa is neurotoxic, its efficacy as a therapeutic for prion disease could not be evaluated.
Unlike quinacrine, treatment with Compound B or anle138b substantially extended the survival of prion-infected mice (15) (16) (17) . Prions from the brains of mice treated with Compound B showed different ratios of mono-to diglycosylated PrP Sc compared with the inoculum (15) , and had a different conformational stability (17) , but it was not determined whether the resulting prions were resistant to further treatment with Compound B. Importantly, Compound B contains a hydrazone functionality likely under physiologic conditions to produce an aryl hydrazine, a toxic metabolite and carcinogen (18) , limiting its utility as a therapeutic (17) . Treatment with anle138b decreased PrP Sc accumulation at early timepoints and changed the size of PrP Sc aggregates, but the resulting prions did not show evidence of altered strain properties. One potential problem with anle138b is the presence of a methylenedioxyphenol group, which has been shown to produce neurotoxic or hepatotoxic effects (19) .
Significance
As people live longer, the prevalence and economic impact of neurodegenerative diseases rise. No cures or effective treatments exist for any of these fatal disorders, so identifying potential therapeutics that extend survival in animal models is vital. Many neurodegenerative illnesses have been shown to be caused by the accumulation of self-propagating misfolded proteins-the hallmark of prion diseases. We report the efficacy of 2-aminothiazoles, which were identified in cell-based screens as antiprion compounds, in extending the lives of prion-infected animals. Efficacy was limited by the development of drug-resistant prions, which is likely to have important implications for creating therapeutics in many different neurodegenerative diseases.
In the work reported here, we describe the oral administration of two therapeutic lead compounds, IND24 and IND81, in wildtype (WT) mice or Tg mice that were infected with mouse-adapted scrapie, CWD or sporadic (s)CJD prions. Although treatment of RML-infected WT mice with both IND24 and IND81 was successful in extending survival up to twofold, the mice eventually exhibited neurologic dysfunction and died.
To (Fig. 1). 2-Aminothiazoles Extended Survival. The 2-aminothiazole (2-AMT) scaffold was identified in a screen for antiprion compounds in cell culture (21) and optimized by medicinal chemistry and pharmacokinetic studies (22, 23) . Two compounds, IND24 and IND81, were selected for efficacy studies in RML-infected Tg (Gfap-luc)/FVB mice (24) expressing WT mouse PrP C . The mice were dosed with 210 mg·kg −1 ·d −1 of either compound from 1 d postinoculation (dpi), until they showed signs of neurologic dysfunction. Treatment with IND24 extended mean survival to 204 ± 5 dpi compared with 118 ± 1 dpi with vehicle alone ( Fig.  2A and Table 1 ). Treatment with IND81 extended mean survival to 193 ± 3 dpi.
Incubation time is dependent on the prion strain, titer, route of inoculation, and host model. Due to the small differences observed in disease onset within cohorts of prion-infected mice, extension in survival can appear highly significant regardless of whether these differences fall within the range of interexperimental variability (25) . Moreover, many statistical tests fail to account for the magnitude of any survival extension. To enable the direct comparison of prion inoculation experiments and provide a quantitative metric for extension in survival, we calculated the survival index: the mean survival time of compoundtreated mice divided by the mean survival time of the vehicletreated control mice on first passage, multiplied by 100. For example, a survival index of 200 shows that treatment extended mean survival time twofold. Continuous treatment with IND24 or IND81 in WT mice resulted in survival indices of 173 ± 4 and 164 ± 3, respectively ( Table 1 ).
Bioluminescence Imaging Predicted Efficacy. Using Tg(Gfap-luc)/ FVB mice, we previously showed that the luciferase reporter under the control of the glial fibrillary acidic protein (GFAP) promoter (24) could function as a surrogate for PrP Sc prion production (26) . Vehicle treatment of prion-infected mice resulted in an increase in the bioluminescence imaging (BLI) signal at ∼60 dpi that plateaued after ∼75 dpi (Fig. 2B ). The BLI signal in both IND24-and IND81-treated mice did not begin to increase until ∼125 dpi and plateaued at ∼150 dpi (Fig. 2B) . Thus, the suppressed BLI signal predicted efficacy beginning at 60 dpi.
2-AMT Treatment Altered the Characteristics of Prions in Brains of
Mice. In addition to survival time, a battery of metrics was used to characterize prion strains, including molecular weight of proteinase K (PK)-resistant PrP, as determined by gel electrophoresis; glycoform ratio, which is PK-resistant mono-to diglycosylated PrP; conformational stability, defined as the resistance to denaturation by guanidine hydrochloride (GdnHCl); spatial distribution of PrP Sc To determine whether our observations were limited to N2a cells, we repeated these studies with CAD5 cells, a neuronal mouse cell line reported to be permissive to infection with a wider range of prion strains compared with N2a cells (20 To characterize further the RML[IND24] prions, brain homogenates from RML[IND24] mice were passaged in Tg(Gfap-luc)/ FVB mice that received either IND24 or vehicle. The mean survival time for the second passage in the presence of IND24 was 166 ± 5 dpi and 165 ± 5 dpi in two independent replicate experiments ( Fig. 4A and Table 1 ). This survival time was ∼40 d shorter than that found on the initial passage of RML prions in mice treated with IND24 or IND81 ( Fig. 2A ; P < 0.001, Logrank test).
Consistent with this shortening of the incubation time, the BLI signal increased rapidly beginning at ∼60 dpi and plateaued at ∼90 dpi (Fig. 4B) . The BLI profiles of the animals in the two independent experiments were virtually superimposable. 4 A and B) . RML[IND24] prions passaged in the absence of IND24 resulted in incubation periods of 187 ± 13 dpi and 188 ± 0 dpi in two independent experiments (Table 1 and Fig. 4D ). The BLI profiles of the animals in the two independent experiments were nearly identical: the BLI signal increased rapidly beginning at ∼125 dpi and continued to rise until the mice were euthanized at ∼190 dpi (Fig. 4E) IND24], the BLI profiles argue that the strains are distinct (compare solid lines in Fig. 4 B and E) (Fig. 4 F and G) Fig. S1B , Table 1 , and Table S1 ). (Fig. 4 H-K) . Cells infected with RML proved highly susceptible to both Compound B (Fig. 4H) and quinacrine (Fig. 4J) , consistent with previous reports (11, 15) . Compound B treatment up to 10 μM was ineffective against the IND24-resistant strain (Fig. 4I) (27) . ME7-infected Tg(Gfap-luc)/FVB mice were dosed with IND24 at 210 mg·kg −1 ·d −1 from 1 dpi and continued until mice showed signs of neurologic dysfunction. Mean survival times were 214 ± 4 dpi for IND24-treated mice and 126 ± 2 dpi for vehicle-treated mice, giving a survival index of 170 ± 4 ( (Fig. 5 A-C) . Although PrP Sc deposition and vacuolation in most regions showed no difference between IND24-and vehicle-treated, ME7-inoculated mice, we found a significant decrease in PrP Sc deposition in the septum (P = 0.003) and the caudate nucleus (P = 0.002, Student's t test with Bonferroni correction; Fig. S2A ), and in vacuolation in the septum ( Fig. S2B ; P < 0.001) of IND24-treated animals.
Because ME7 does not infect N2a cells (28) (Table S2 ). IND24 treatment reduced PrP Sc similarly in both ME7-and ME7[IND24]-infected CAD5 and LD9 cells (Fig. 5 D-G) . Glycoform ratios showed no significant differences (Fig. S2C) .
Efficacy of Delayed Treatment Was Strain-Dependent. To test the effects of delayed treatment on survival time, we treated RMLand ME7-infected animals with IND24 starting at 60 dpi. The survival of RML-infected animals with delayed treatment was extended to 211 ± 1 dpi, a survival index of 179 ± 1, indistinguishable from treatment starting from 1 dpi (Fig. 5H and Table 1 ). Conversely, ME7-infected animals treated from 60 dpi survived 158 ± 5 dpi, giving a survival index of 125 ± 5, a significant decrease compared with treatment starting at day 1 (P < 0.001, Log-rank test; Fig. 5H and Table 1 ). These results suggest that RML and ME7 prions propagate with different kinetics. ·d −1 beginning at 1 dpi. Tg4053 mice overexpressing WT mouse PrP (29) were inoculated with RML prions and treated with IND24, increasing survival from 51 ± 3 dpi to 112 ± 4 dpi, producing a survival index of 220 ± 14 ( Fig. 6A and Table 2 ). This result demonstrates that IND24 is effective against transgene-expressed PrP.
Next, we treated Tg1014 mice expressing a chimeric human/ mouse PrP (30) , which are capable of replicating both mouse and human prions. Following RML-infection, IND24 treatment produced a survival index of 203 ± 12 ( Fig. 6B and Table 2 ). However, when we inoculated sCJD(MM1) prions (the most common human prion strain) into Tg1014 mice, mean survival times were 73 ± 2 dpi and 78 ± 1 dpi for IND24-treated and vehicle-treated Tg1014 mice, respectively, giving a survival index of 94 ± 2 ( Fig. 6C and Table 2 ), indicating that efficacy is dependent on the inoculating strain, not the PrP sequence of the host.
We then infected Tg2669 mice, expressing WT human PrP with the M129 polymorphism, with sCJD(MM1) prions and treated them with IND24. The mean survival times of these mice were 144 ± 2 dpi and 143 ± 2 dpi for IND24 and vehicle treatments, respectively, giving a survival index of 101 ± 2 ( Fig. 6D and Table 2 ). To test the possibility that IND24 treatment could have a limited effect masked by the high prion titer in the inoculum, we treated Tg1014 and Tg2669 mice infected with a 1:1,000 dilution of the original sCJD(MM1) inoculum. Again, we observed no increase in survival in IND24-treated animals compared with vehicle-treated mice: respective survival indexes were 102 ± 5 and 103 ± 3 for Tg1014 and Tg2669 mice (Fig. 6 E and F and Table 2 ). Finally, we inoculated sCJD(VV2) prions (the second most common human prion strain) into Tg(HuPrP, V129)152 mice that express WT human PrP with the V129 polymorphism (31, 32) . IND24 treatment failed to produce any extension in lifespan: the survival index of treated mice was 96 ± 5 ( Fig. 6G and Table 2 ). Together, these results indicate that IND24 treatment had no effect on the survival of Tg mice infected with the two most common human CJD prion strains.
IND24 Treatment Prolonged the Lives of Animals Infected with CWD.
To assess whether IND24 antiprion efficacy was limited to mouse-adapted scrapie strains, we inoculated Tg mice expressing elk PrP C with brain homogenate from an elk with CWD, and treated them with IND24. Vehicle-treated mice survived 108 ± 3 dpi, but mice treated with IND24 at 210 mg·kg
, starting the day after inoculation, survived 237 ± 0 dpi, giving a survival index of 219 ± 3 ( Fig. 6H and Table 2 ).
Discussion
The lack of any drugs that halt or even slow neurodegeneration is becoming a crisis. In developed and developing countries, people over 65 y of age represent the fastest growing segment of these populations. For most neurodegenerative diseases, the greatest risk factor is age. In Alzheimer's disease, the risk increases from 5% at age 65, to 20% at age 75, and to 40% at age 85 (33) .
We began with an unbiased screening of compounds to identify those that substantially lower PrP Sc levels. Among such compounds were several 2-AMTs (21). Several dozen analogs were subsequently synthesized to optimize the potency as well as the drug-like properties of these 2-AMTs (22, 23) . In the studies reported here, two 2-AMTs significantly extended the lives of mice infected with mouse-adapted scrapie or with CWD prions (Figs. 2A, 5H , and 6H) but the mice eventually showed signs of progressive neurologic dysfunction, which required them to be euthanized.
To understand why mice treated with 2-AMTs eventually succumbed to CNS disease, we serially passaged the prions from RML-infected mice that received the AMT IND24, seemed to restore the original properties of RML prions and render them susceptible to IND24.
While screening and medicinal chemistry optimization resulting in IND24 and IND81 were performed in RML-infected N2a cells (21-23), IND24-resistant prions were not able to propagate in N2a cells, thereby making the cells unable to predict the emergence of resistance. CAD5 cells were similarly sensitive to IND24 following RML infection, so even though they are able to propagate the IND24-resistant strain, they would not have been more predictive of resistance than N2a cells. Although IND24 treatment of ME7-infected CAD5 and LD9 cells resulted in minimal reductions in PrP Sc levels, it did prolong the survival of ME7-infected mice from 126 dpi to 214 dpi (a survival index of 170), similar to IND24 treatment of RML-infected mice. Biochemical analysis and infection experiments indicated that the resulting ME7[IND24] prion strain seems largely unaltered. Taken together, these observations imply that the extension in survival by IND24 treatment of ME7 infection may be caused by impaired propagation of prions rather than through strain adaptation. These results underscore the limitations of cell culture for predicting the results of animal studies, but raise the possibility that some compounds with limited efficacy in cells may prove more effective in animals.
Despite the efficacy against RML and ME7 prion strains, IND24 treatment of multiple Tg mouse lines inoculated with the two most common CJD prion strains did not lead to any extensions in survival, highlighting the need to validate therapeutics intended for human use in the most relevant animal models. This resistance seems to be an inherent property of both the MM1 and VV2 CJD strains, but the lack of a cell culture system for the propagation of human prions limits this interrogation. Although the results in humanized mice were disappointing, IND24 was effective in extending the lifespan of mice infected with CWD. This extension marks the successful treatment of a naturally occurring prion strain and demonstrates the validity of cell-based drug discovery for identifying compounds to treat neurodegenerative disorders.
We have generated additional compounds based on the 2-AMT and other chemical scaffolds that are more potent than IND24 and IND81 (34) (35) (36) ; whether these compounds will show efficacy against human prions remains to be determined. However, the rapid acquisition of IND24 resistance and the strainspecific efficacy of the compounds, combined with the observation that some CJD patients may harbor more than one prion strain (reviewed in ref. 37 ), indicate that a single therapeutic agent may not be sufficient to treat individuals with prion diseases.
Some investigators have argued for the strain selection mechanism to explain prion mutagenesis (38, 39) . Our previous studies on serial passage of variant CJD and synthetic prions in Tg mice led to similar conclusions: the selection pressure was for more rapid prion formation, i.e., shorter survival times (9, 30, 40) . It is unknown whether IND24 selected for a subpopulation of prions in the RML inoculum that replicates more slowly or induced a conformational change. The RML[IND24] prions in brain homogenates prepared from ill mice remained resistant to IND24 in CAD5 cells for more than 20 passages. These observations suggest that IND24 resistance was unlikely to require that the compound be bound to the RML[IND24] prions. Despite all of the data presented here, the mechanisms by which IND24 prolonged incubation times and led to resistance remain to be established.
The studies reported here have broad implications for the development of pharmacotherapeutics for many neurodegenerative diseases. Deciphering the mechanisms of drug resistance and building mixtures of medications to treat these dreaded disorders would seem paramount in view of the widening spectrum of disease thought to be caused by prions. Importantly, the frequency of IND24-resistant prions emerging appears to approach 100% (Tables 1 and 2 ). All of the animals receiving RML, ME7, or CWD prions showed a doubling of the incubation time when treated with IND24 or IND81, but none survived longer, indicating that efficacy of these 2-AMTs was limited. Our findings portend the emergence of a discipline where drug resistance is governed by the "laws" of conformational mutagenesis of protein structure instead of nucleic acid changes that give rise to amino acid substitutions.
Materials and Methods
Materials. CAD5 and LD9 cells were a gift from Charles Weissmann. Minimal essential medium (MEM) with Earle's salts; Dulbecco's Modified Eagle Medium (DMEM) high glucose 1× with 4.5 g/L D-glucose and L-glutamine and without sodium pyruvate; Opti-MEM; FBS; penicillin-streptomycin (penstrep; each at 10,000 units per mL); GlutaMAX; DTT (DTT; 0.5 M 10×); 4× loading buffer and PK were purchased from Invitrogen. Enzyme-free cell dissociation buffer was purchased from Millipore. IND24 and IND81 were synthesized by ChemVeda.
Animal Husbandry and Tissue Preparation. All protocols were approved by the University of California San Francisco Animal Care and Use Committee. All mice were bred in our facility. Tg(Gfap-luc)/FVB and Tg4053 mice were on the due to problems observed with long-term dosing of male mice (17) . Mice were inoculated intracerebrally with 30 μL of 1% brain homogenate containing RML, ME7, sCJD(MM1), sCJD(VV2), or CWD prions, unless otherwise stated, when 30 μL of 0.001% sCJD(MM1) brain homogenate (generated by serial tenfold dilution), was used. RML and ME7 prions were serially passaged multiple times in WT CD1 mice. sCJD(MM1) and sCJD(VV2) inocula were prepared from histopathologically confirmed patients, in which the PrP ORF sequence had been confirmed free of mutation, and were previously reported (32) . The CWD isolate used has previously been reported as isolate Elk1 (41) . Animals were observed every day for signs of neurologic disease. Mice were diagnosed with prion disease when they exhibited three or more neurologic signs characteristic of prion disease, as described (42) . Upon diagnosis, mice were euthanized and their brains collected. The left hemisphere was snap-frozen on dry ice, then stored at −80°C for biochemical analysis; the right hemisphere was fixed for pathological analysis.
Tg Mouse Models. Tg mice expressing mouse PrP, chimeric human (Hu)/mouse PrP, HuPrP with the V129 polymorphism, and ElkPrP, denoted Tg4053, Tg1014, Tg152, and Tg12584 respectively, have been previously reported (29) (30) (31) (32) 41) . Hemizygous Tg4053 and Tg1014 mice, and homozygous Tg152 and Tg12584, the latter designated with " +/+ ", were used for experiments. For Tg2669 mice expressing human PrP with the M129 polymorphism, a construct was amplified by PCR from the plasmid pcDNA3.HuPrP using the following primers: 5′-CTATATGTCGACACCATGAACTGGGCACCCGCA-3′ (forward) and CTATATGTCGACCTAGGGCCGCAGCAGCCCCA-3′ (reverse). Following digestion with SalI, the PCR product was inserted into SalI-digested cos. Tet cosmid vector, which drives neuronal expression of proteins using the hamster Prnp promoter. Preparation of the vector and microinjection were performed as previously reported (43) . Three lines of Tg mice were obtained, one of which (Tg2669) was selected for further analysis. Tg2669 mice were maintained on an FVB/Prnp 0/0 knockout background. Expression levels of HuPrP in the brains of hemizygous Tg2669 mice were determined to be four to five times higher than that of WT FVB mice. The validity of the transgene sequence in Tg2669 mice was verified by DNA sequencing. Homozygous Tg2669 +/+ mice were generated by intercrossing hemizygous mice and confirmed by backcrossing.
Long-Term Dosing of Compounds. Dosing was performed as previously reported (17) . Briefly, compounds were dissolved in 100% (vol/vol) PEG400 and stored at −4°C until use. Samples were diluted to make final dosing concentrations of 1.25% (vol/vol) PEG400 in the initial RML infection studies, and 0.125% (vol/vol) PEG400 in all other studies in a complete rodent liquid diet (Bio Serv, product no. F1256SP). For vehicle-treated mice, pure PEG400 was diluted appropriately into the previously prepared rodent liquid diet. The amount of food served was based on the number of animals in each cage and replaced by new batches every 2-4 d. All dosing was performed at 210 mg·kg
Bioluminescence Imaging. Tg(Gfap-luc) mice were a generous gift from Caliper Life Sciences, from which a homozygous line was generated (44) . Mice were imaged weekly using an IVIS Lumina imaging system (Caliper Life Sciences). In brief, mice were injected intraperitoneally with a solution of D-luciferin potassium salt (Gold Biotechnology) in PBS, pH 7.4 (Invitrogen), receiving 50 mg D-luciferin per kilogram body weight. The mice were then anesthetized using an isoflurane-oxygen gas mix and imaged after 10 min for 30-60 s under anesthesia. The bioluminescence signal was quantified from images using Living Image 4.2 software (Caliper).
Conformational Stability Assay. Samples (10 μL of 20% brain homogenate) were incubated with GdnHCl, in increments of 0.5 M from 0 to 4 M, at 22°C for 2 h. The samples were subsequently diluted with lysis buffer to a final concentration of 0.4 M of GdnHCl. PK was added at a final concentration of 50 μg/mL and the samples were incubated at 37°C for 1 h. Phenylmethylsulfonyl fluoride (final concentration of 1 mM) was added to stop the PK digestion. Samples were ultracentrifuged at 100,000 × g for 1 h, and the pellets resuspended in loading buffer. The samples were subsequently analyzed by immunoblot.
Immunoblotting. For immunoblot analysis, brain samples were digested with 20 μg/mL PK at 37°C for 1 h. PrP Sc pellets from 500 μL of PK-digested samples were collected and resuspended with SDS sample running buffer and 0.1 M DTT. Samples were heated to 100°C for 10 min and run in a 4-12% Tris· glycine SDS gel (Invitrogen). The gel was transferred to PVDF membrane using an iBlot (Invitrogen) and the membrane was blocked with 5% milk for 30 min. The membranes were subsequently incubated overnight with horseradish peroxidase (HRP)-conjugated HuM-D13 or HuM-P Fabs and washed 3× with Tris-buffered saline with Tween-20 for 10 min before developing with an enhanced chemiluminescence reagent (Invitrogen). Bands on immunoblots were quantified using ImageJ 1.46r (45) . Total intensity for an area encompassing each band was measured, and average background was subtracted. Normalized intensities were totaled for each lane. For the conformational stability assay, a ratio was calculated comparing each lane to the control (0 M GdnHCl), and these ratios were averaged across multiple samples. For glycoform proportions, a ratio was calculated for each normalized band intensity compared with the sum of the three isoforms, and these ratios were averaged across multiple samples.
Pathology. Brains were immersion-fixed in 10% (vol/vol) buffered formalin. Fixed samples were paraffin-embedded, sectioned, and then stained with H&E, or processed by immunohistochemistry for PrP with the R2 monoclonal antibody, as described previously (46) . Images were taken at 20× and 40× magnifications using the SpotFlex camera and program on the Leica DM-IRB microscope. Neuropathological analyses were performed on an average of 5-11 mice to qualify for statistical calculations. PrP Sc concentrations were determined by a visual assessment of the intensity of immunohistological staining, multiplied by the area of the brain region occupied by staining, and divided by the cross-sectional area of the brain region. The intensity of immunostaining was given a value of 1 for barely detectable, 2 for mild, 3 for moderate, and 4 for strongly intensive. Vacuolation in a brain region was estimated by the percent of an area occupied by vacuoles (vacuolation score), multiplied by the fraction of a brain region containing vacuoles, and divided by the cross-sectional area of the brain region. PrP Sc accumulation and vacuolation were evaluated by a single rater (S.J.D.).
Cell Culture. Cells were infected with RML or ME7 prions as previously described (47) . All cell lines were maintained at 37°C in their respective media in 100-mm plates and fed with fresh media every 2-3 d. N2a cells were maintained in DMEM supplemented with 1% GlutaMAX, 100 units pen-strep and 10% FBS; LD9 cells maintained in MEM supplemented with 90 units penstrep and 9% FBS; CAD5 cells maintained in Opti-MEM supplemented with 90 units pen-strep and 9% FBS. Dividing cells were plated at 10% confluency and split 1:10 when they become confluent. Cells were incubated with IND24 at the doses indicated over 5 d with refeeding. IND24 was diluted in DMSO, with 50-μL final volume in 10 mL of media. At the end of the 5-d treatment period, lysis buffer (100 mM Tris·HCl, pH 8.0; 150 mM NaCl; 0.5% Nonidet P-40; 0.5% sodium deoxycholate) was added to cells, and protein concentrations were measured using a bicinchoninic acid protein assay kit (Fisher). Protein extracts were normalized to 1 mg/mL total protein with lysis buffer before PK digestion. Lysates were digested with 20 μg/mL PK at 37°C for 1 h. The reaction was stopped with phenylmethylsulfonyl fluoride (2 mM final concentration). The samples were ultracentrifuged at 100,000 × g for 1 h, resuspended in loading buffer, and subjected to immunoblot analysis.
Statistical Analysis. All calculations were performed with Stata 11 (Stata Corp.), or Prism 5 (GraphPad Software Inc.). 
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